Myoconda (clarithromycin/clofazimine/rifabutin) - RedHill
RedHill: Corporate Presentation (RedHill) - Aug 6, 2016 - Anticipated DSMB safety and futility analysis of P3 MAP US trial (NCT01951326) for Crohn’s disease in Q4 2016 
Anticipated DSMB Inflammatory Bowel Disease
http://ir.redhillbio.com/
 
Aug 6, 2016
 
 
63178b75-3770-44fe-bbaf-94b956e2a864.jpg